CSPC Innovation Pharmaceutical (300765.SZ) subsidiary SYS6005 antibody drug conjugate obtains notice of approval for clinical trial of drug.

CSPC Innovation Pharmaceutical (300765.SZ) announced that its controlling subsidiary, CSPC PHARMA JuShi Biopharmaceutical Co., Ltd. ("JuShi Biopharmaceutical"), recently received the Drug Clinical Trial Approval Notification from the National Medical Products Administration for SYS6005. The company will soon begin clinical trials. SYS6005 is a monoclonal antibody drug conjugate that can bind to specific receptors on the surface of tumors, enter cells through endocytosis, and release toxins to kill tumor cells. SYS6005 has been classified as a category 1 biologic for therapeutic use, with the approved indication for advanced tumors. It is expected to be used in the treatment of hematologic malignancies, ovarian cancer, non-small cell lung cancer, among others. Preclinical studies have shown that SYS6005 has a good anti-tumor effect on various types of cancer and is expected to demonstrate promising therapeutic efficacy in subsequent clinical trials. The product has multiple patent applications submitted both domestically and internationally.